# The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Study · id `cardio:ct-nct06030843` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06030843](<https://clinicaltrials.gov/study/NCT06030843>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06030843

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06030843. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-01 (actual); primary completion 2026-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06030843, source copy `cardio:ctgov-nct06030843-2026-06-16`, retrieved 2026-10-26)
- Started: 2025-03-01 (actual) (ClinicalTrials.gov record NCT06030843, source copy `cardio:ctgov-nct06030843-2026-06-16`, retrieved 2026-10-26)
- Primary completion: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT06030843, source copy `cardio:ctgov-nct06030843-2026-06-16`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06030843, source copy `cardio:ctgov-nct06030843-2026-06-16`, retrieved 2026-10-26)
- Countries: Thailand (ClinicalTrials.gov record NCT06030843, source copy `cardio:ctgov-nct06030843-2026-06-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06030843-2026-06-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
- Acronym: TREAT-CRS
- Condition: Empagliflozin in Cardiorenal Syndrome Type 1
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Placebo
- Lead sponsor: Chulalongkorn University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: baaeda5d12051dc0319bca60b09ea6ff5f75727a3f5ef56d5b169b86a6b0ed5c
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
